MirZyme Therapeutics is developing a digital diagnostic algorithm that analyzes blood test results to predict the risk of preeclampsia in pregnant women, enabling timely intervention. The company also offers tailored therapeutics aimed at preventing preeclampsia and fetal growth restriction, addressing critical health risks that can lead to maternal and infant mortality.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Preeclampsia, a pregnancy complication characterized by high blood pressure and organ damage, poses significant risks to both maternal and fetal health, potentially leading to mortality if not detected and managed promptly. Current methods for predicting preeclampsia risk often lack the accuracy needed for timely intervention, resulting in delayed preventative measures. Additionally, limited therapeutic options exist to directly address the underlying causes of preeclampsia and prevent its progression.
Solution
MirZyme Therapeutics is developing an end-to-end solution for preeclampsia, encompassing predictive diagnostics and targeted therapeutics. Their digital diagnostic algorithm analyzes blood test results during the second trimester to identify pregnant women at high risk of developing preeclampsia. This early risk assessment enables clinicians to implement timely preventative strategies and personalized treatment plans. Furthermore, MirZyme is developing a pipeline of therapeutics designed to prevent preeclampsia and mitigate the risk of Small for Gestational Age (SGA) babies, addressing both prediction and prevention.
Target Audience
The primary target audience includes obstetricians, maternal-fetal medicine specialists, and other healthcare providers involved in prenatal care, as well as pregnant women at risk of developing preeclampsia.
Features
- Proprietary digital diagnostic algorithm for early preeclampsia risk prediction using blood biomarkers
- Clinical validation of the diagnostic algorithm through prospective human trials
- Pipeline of tailored therapeutics targeting the underlying causes of preeclampsia
- Therapeutics designed to prevent fetal growth restriction and improve neonatal outcomes
- Intellectual property portfolio including global patents in 30 countries